6.45
+0.015(+0.23%)
Currency In USD
| Previous Close | 6.43 |
| Open | 6.47 |
| Day High | 6.49 |
| Day Low | 6.15 |
| 52-Week High | 11.8 |
| 52-Week Low | 4.44 |
| Volume | 100,828 |
| Average Volume | 172,580 |
| Market Cap | 164.07M |
| PE | -5.56 |
| EPS | -1.16 |
| Moving Average 50 Days | 7.69 |
| Moving Average 200 Days | 7.53 |
| Change | 0.02 |
If you invested $1000 in Nuvectis Pharma, Inc. (NVCT) since IPO date, it would be worth $1,983.08 as of August 18, 2025 at a share price of $6.445. Whereas If you bought $1000 worth of Nuvectis Pharma, Inc. (NVCT) shares 2 years ago, it would be worth $431.68 as of August 18, 2025 at a share price of $6.445.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
GlobeNewswire Inc.
Aug 11, 2025 8:30 PM GMT
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients wit
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
GlobeNewswire Inc.
Jul 31, 2025 11:45 AM GMT
Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases; thrombocytopenia successfully managed with int
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
GlobeNewswire Inc.
Jul 08, 2025 12:00 PM GMT
Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs.The market leading epidermal growth factor recep